Objective: HIV-1-infection infers an increased cardiovascular risk where gut dysbiosis and microbial translocation may contribute. We assessed TMAO, a microbial metabolite with atherosclerotic properties, in plasma of HIV-1-infected individuals at different clinical stages in relation to inflammatory markers, cardiovascular events and gut microbiota.
Introduction
Despite efficient antiretroviral treatment (ART), HIV-1-infected individuals are at increased risk of cardiovascular disease (CVD) [1] , where chronic immune activation and inflammation secondary to HIV-induced translocation of microbial products and metabolites are potential contributory factors. Recent evidence suggests a linkage between compositional changes of intestinal microbiota and dysregulation of the gut immune barrier function in HIV [2] [3] [4] [5] . Of note, several studies have observed decreased microbiome diversity in HIV patients that is directly correlated with increased immune activation [3, [6] [7] [8] .
Trimethylamine-N-oxide (TMAO) has recently been identified as a microbial metabolite with pro-atherosclerotic properties [9, 10] . Elevated levels of TMAO have been associated with increased cardiovascular risk [9] [10] [11] [12] [13] [14] . TMAO is the primary metabolite of trimethylamine (TMA) that is produced by gut bacteria and further converted to TMAO by flavin-containing monooxygenase (FMO 3 ) in the liver [10, 13, 15, 16] . Diets rich in red meat, eggs and full-fat dairy products provide substrate for TMA conversion and may subsequently increase TMAO levels. Although plasma levels of TMAO are governed by diet, FMO 3 enzyme activity and renal clearance, growing evidence suggests that the gut microbial composition is directly linked to circulating TMAO levels in a healthy population [10, 15, 17, 18] . Today, there are two main bacterial pathways generating TMA through degradation of dietary substrates in humans: the CutC/CutD pathway [19, 20] and the Cnt A/B pathway [21, 22] . Notably, genetic components for TMA conversion are detected in Firmicutes, Proteobacteria and Actinobacteria, but appears to be absent in Bacteroidetes [20, 23] .
Considering the potential role of gut microbiota in HIV pathogenesis and the demonstrated effects of TMAO on the atherosclerotic process, we hypothesized that TMAO production would increase over time as a result of HIVassociated dysbiosis, thus presenting a link between gut microbiota, systemic inflammation and cardiovascular risk in HIV. Exploring this hypothesis, we assessed levels of TMAO in two longitudinal cohorts of primary and chronic HIV-1-infected individuals before and after ART initiation in relation to systemic inflammation and microbial composition of the gut. The role of TMAO in relation to cardiovascular comorbidity was also assessed in a cross-sectional cohort of HIV-1-infected individuals on long-term effective ART.
Methods

Study design
We studied HIV1-infected individuals from two longitudinal studies (before and after ART) [8, 24] (Table 1) and one cross-sectional study cohort [25] in comparison to healthy controls (Table 2) . Circulating TMAO, markers of systemic inflammation, viral load and cellular immunity were assessed in plasma and whole blood. Additionally, in one cohort (chronic HIV-1) [8] , the bacterial composition in stool was assessed by high-throughput 16SrRNA sequencing at baseline and after initiation of ART.
Study cohorts
Primary HIV-infected cohort Seventeen participants with primary HIV-1 infection (participants of the Quest study) [24, 26] were included with sampling within 2 weeks of HIV acquisition and 3-4 months after introduction of ART. Chronic HIV-1 cohort Twenty-two participants were included from a study on microbiota and immune status in treatment-naive chronic HIV-1-patients [8] followed for a median of 10 months (IQR 4-15) after ART initiation. Patients were recruited from the HIV outpatient clinic at Karolinska University Hospital, Stockholm, Sweden. Nine sex-matched and age-matched HIV-1-negative individuals were included, consisting of household members and partners of the patients.
Chronic antiretroviral therapy cohort One hundred and one HIV-1 patients on long-term ART (median 9 years, IQR 5-15) were included from a crosssectional study of vitamin D levels in HIV-1-infected individuals from the HIV outpatient clinic at South General Hospital, Stockholm, Sweden, 2012 [25] . Sixyear follow-up data on time to first cardiovascular events (unstable angina, acute myocardial infarction, transitory ischemic attack and stroke) were registered from medical files. HIV-1-negative healthy controls (n ¼ 30) consisting of staff at the Karolinska University Hospital were included from the same study.
As an external control, 23 sex-matched and age-matched HIV-1-negative individuals were selected from a previously presented population-based cohort in the Stockholm region of Sweden [27] .
Ethics
All participants provided written informed consent and the study was performed in accordance with the 
Trimethylamine-N-oxide
Analysis of plasma levels of TMAO was performed by liquid chromatography/tandem mass spectrometry (LC/ MS/MS) at Swedish Metabolomics Centre, Umeå, Sweden utilizing a protocol previously described [27] (PHI, chronic ART with controls and sex-matched and age-matched controls), and in the laboratory of Bevital AS (www.bevital.no; Chronic HIV-1 cohort with controls).
Soluble inflammation markers
Limulus Amebocyte Lysate (LAL; Lonza; Basel, Switzerland) and Human sCD14 Quantikine ELISA (R&D, Minneapolis, Minnesota, USA) were used to measure plasma lipopolysaccharide (LPS) and soluble CD14 (sCD14), as described [8, 25] TMAO, inflammation and dysbiosis in HIV-1 Missailidis et al. 1591 LPS-binding protein (LBP; Hycult Biotech, Uden, The Netherlands), and D-dimer (Technoclone, Vienna, Austria) were determined in plasma samples by ELISA according to the manufacturers' instructions.
Microbiota analysis
Stool samples were collected and stored at À808C until further use. Microbiota composition was determined by 16S rRNA sequencing targeting V3-V4 region of 16S gene using Illumina MiSeq and analysed using the established bioinformatics pipeline as described previously [8] . A post hoc analysis was performed with a special focus on gut bacteria with the propensity to produce TMA (defined by in-vitro studies and/or genomic presence of the TMA-producing enzymes CutC/D and Cnt A/B) [19, 20, 22, 23, 28, 29] ( Table 3) . 
Statistical analyses
Results
Patient characteristics and demographics
The median age was similar in the PHI and the chronic HIV-1 cohort with healthy controls (Table 1 ). The PHI cohort was dominated by MSM of Caucasian origin, whereas the chronic HIV-1 cohort had a more heterogeneous distribution of sex, ethnic origin and sexual orientation (Table 1 ). All patients in the PHI cohort were started on protease inhibitors. In the chronic HIV-1 cohort, 65% were started on a protease inhibitor 1592 AIDS 2018, Vol 32 No 12 and 35% on a nonnucleoside reverse-transcriptase inhibitor (NNRTI)-based regiment (Table 1) . Patients in the chronic ART cohort were significantly older than their healthy controls (P ¼ 0.001) and were predominantly MSM of Caucasian origin (Table 2) . Twenty-four percent of the HIV-1-infected individuals were on a protease inhibitor and 54% on a NNRTIcontaining regiment (Table 2) .
Trimethylamine-N-oxide levels were decreased in treatment-naive HIV-1-individuals and increased to normal levels with treatment Levels of TMAO were lower in untreated HIV individuals and increased significantly after ART, both in primary infected (median 1.28 vs. 2.30 mmol/l, P ¼ 0.040) and chronic HIV-infected individuals (median 2.09 vs 4.47 mmol/l, P < 0.001; Fig. 1a) . Despite increased TMAO levels at follow-up in the chronic HIV-1 cohort, levels did not differ significantly from the corresponding healthy controls (P ¼ 0.075; Fig. 1a) .
Notably, chronic HIV-1-individuals with longstanding ART had similar levels as their healthy controls (P ¼ 0.89). To account for the difference in age between the chronic ART cohort and their controls, we introduced an age-matched and sex-matched, HIV-1-negative control group (Table 2) . Compared with the age-matched and sex-matched controls, chronic ART individuals had significantly lower TMAO levels (P ¼ 0.008) and higher eGFR (P < 0.001; Fig. 1a ). However, a one-way ANCOVA conducted to compare TMAO levels found no significant difference in mean TMAO levels (F (1, 106) ¼ 0.563, P ¼ 0.455) between the two cohorts whenever controlling for eGFR.
Plasma trimethylamine-N-oxide and correlations with bacterial composition in stool Spearman correlation analysis between bacterial taxa and TMAO levels revealed several interesting findings at different taxonomical levels. Thus, at baseline, we found that TMAO levels were inversely correlated with Bacteroidetes (Rho: À0.62, P ¼ 0.002), and positively correlated with Firmicutes (Rho: 0.65, P ¼ 0.001). Additionally, baseline plasma TMAO levels were inversely correlated with the genera Alistipes (Rho: À0.47, P ¼ 0.029), Bacteroides (Rho: À0.58, P ¼ 0.004), Odoribacter (Rho: À0.60, P ¼ 0.003), Parabacteroidetes (Rho: 0.52, P ¼ 0.014) and positively correlated with Prevotella (Rho 0.44, P ¼ 0.039); all members of the Bacteroidetes phyla. Furthermore, the genus Suturella, a member of the Proteobacteria phylum was inversely correlated (Rho: À0.64, P ¼ 0.001; Fig. 1b) . However, at follow-up, these associations were no longer present and only a positive association between TMAO and Dialister spp. (Rho: 0.64, P ¼ 0.007), member of the Firmicutes phylum, was observed (Fig. 1b) .
TMAO, inflammation and dysbiosis in HIV-1 Missailidis et al. 1593 Fig. 1 . Distribution of plasma trimethylamine-N-oxide levels and correlation to bacterial genera in faecal samples. TMAO levels in primary infected and chronic HIV-1-infected individuals followed from baseline (BL) to follow-up (FU) after 4-10 months ART treatment, compared with HIV-1-infected individuals on long-term ART and HIV-1-negative controls (a). P values are generated by Wilcoxon signed-rank (BL-FU) and Mann-Whitney U test. Spearman correlation heat map of plasma TMAO and relative abundance of genera in faecal sample of HIV-1-patients at baseline (b). Only 15 patients at follow-up because of missing faecal samples. Only bacterial genera with more than 0.001% abundance present in at least 75% of all patient samples were included. ART, antiretroviral therapy; TMAO, trimethylamine-N-oxide. Ã P value <0.01, ÃÃ P value <0.001.
Relative abundance of trimethylamine-producing bacteria did not change with antiretroviral therapy initiation and did not correlate with circulating trimethylamine-N-oxide or systemic inflammation As plasma levels of TMAO are partly regulated by TMAproducing gut bacteria, we further assessed the relative abundance of bacteria with the propensity to produce TMA before and after initiation of ART at genus level ( Table 3 ). The relative abundance of TMA-producing bacteria did not significantly increase after ART, but remained similar to controls (data no shown). Moreover, changes in the relative abundance of TMA-producing bacteria over time (DTMA ¼ follow-up À baseline levels) neither correlate with the observed changes in circulating TMAO nor with changes in circulating sCD14, LPS, LBP, and D-dimer (data not shown).
Baseline CD4
R /CD8 R ratio, but not viremia, inflammation or use of antiretroviral therapy, predicted increased levels of trimethylamine-Noxide at follow-up To assess if immune status, HIV viremia and inflammation predicted TMAO levels at baseline and follow-up, we assessed the individual cohorts by repeated measure ANOVA and linear regression analysis.
In the PHI and chronic HIV-1 cohorts, TMAO levels did not associate with male sex, Caucasian origin or MSM status. Age, viral load, CD4 þ cell count or CD4 þ /CD8 þ ratio did not predict TMAO levels in either cohort, nor did they associate with change in TMAO levels (DTMAO: follow-up À baseline levels) with one exception: in the chronic HIV-1 cohort, we found that higher baseline CD4 þ
/CD8
þ ratio predicted increased DTMAO (B ¼ 11.92, P ¼ 0.016). None of the inflammatory markers (sCD14, LPS, LBP, D-dimer) predicted TMAO levels or DTMAO in the chronic HIV-1 cohort. Moreover, in the chronic HIV-1 cohort, neither use of protease inhibitor nor NNRTI predicted follow-up TMAO levels, or DTMAO.
In the chronic ART cohort, multiple regression analysis demonstrated that neither preART-VL, CD4
þ ratio predicted TMAO, whenever controlling for age, MSM, eGFR, years with HIV, years of ART and years with undetectable viral load. Similarly, markers of baseline inflammation (hsCRP, sCD14 and LPS) neither predict TMAO levels nor did use of protease inhibitor or NNRTI have a significant effect on TMAO levels.
Higher trimethylamine-N-oxide levels did not infer a significantly increased risk for cardiovascular events During 6 years follow-up, there were six registered cardiovascular events in the chronic ART cohort.
Although the study was not powered to predict cardiovascular events, the highest tertile of TMAO (>4.93 mmol/l) was nonsignificantly associated with a 2.8-fold risk [hazard ratio 2.76: 95% confidence interval (CI) 0.29-26.70, P ¼ 0.38].
Lack of increase in plasma trimethylamine-Noxide levels after antiretroviral therapy initiation associated with loss of Bacteroidetes and increased lipopolysaccharide levels Intrigued by the strong association between baseline CD4 þ /CD8 þ ratio and increased TMAO levels after ART initiation in the chronic HIV-1 cohort we further assessed the cohort with regards to changes in TMAOlevels.
We found that increased TMAO levels after ART initiation (DTMAO >1 mmol/l), were present in a subgroup of 10 HIV individuals whereas no increase (D TMAO <1 mmol/l) was observed in 11 individuals (Fig. 2a) . Individuals with increased TMAO levels had significantly higher CD4 þ /CD8 þ ratio at baseline (Fig. 2b ) compared with patients with no increase. The two groups had a similar age and sex distribution but in the group with increased TMAO levels, more individuals were treated with protease inhibitor (80%), compared with the group with no increase (50%; P ¼ 0.210). On the basis of the hypothesis that lower CD4
þ ratio may reflect a more dysregulated gut microbiota, we compared the microbial composition in individuals with increase versus no increase in DTMAO levels in relation to corresponding healthy controls.
We found that treatment-naive HIV-individuals were similar to controls in relative abundance of Firmicutes, Bacteroidetes, Proteobacteria and Actinobacteria. After ART initiation, HIV individuals with increased DTMAO remained stable in their composition of gut microbiota, whereas individuals with no increase demonstrated a significant reduction in relative abundance of Bacteroidetes (P ¼ 0.023) and a corresponding nonsignificant expansion of Firmicutes and Proteobacteria compared with controls (Fig. 2c) .
Moreover, after ART initiation, HIV individuals with no increase had significantly higher levels of LPS compared with individuals with increased DTMAO (P ¼ 0.01; Fig. 2d ). Of note, LPS levels correlated inversely with relative abundance of Bacteroidetes at follow-up (Rho -0.90, P ¼ 0.037).
Discussion
Our study explored circulating TMAO levels in primary and chronic HIV-1 before and after ART and in HIV-1-infected individuals on long-term effective ART. In support of our original hypothesis we found that TMAO levels increased over time with ART. However, regardless of treatment length, TMAO levels in HIV-1-infected individuals remained similar to healthy controls and were not significantly affected by treatment regime, immune status or degree of systemic inflammation. Notably gut dysbiosis was more pronounced in patients without increase in TMAO levels after ART initiation.
The observation that HIV-1-infected individuals had similar TMAO levels as healthy controls has been reported by other studies assessing circulating TMAO and CVD in HIV [32] [33] [34] . Contrary to population-based studies [9] [10] [11] 13] these studies provide no conclusive evidence that elevated TMAO has a strong impact on atherosclerotic burden, prevalent CVD or adverse cardiac events in HIV-infected individuals [32] [33] [34] [35] . Similarly, although the study was not powered to detect relation to cardiovascular events, we found no significant risk with increasing TMAO levels (P ¼ 0.38) in well controlled HIV-1-infected individuals on long-term ART. Furthermore, our observation suggesting that ART initiation increases TMAO levels was previously reported in a nested case-control study by Haissman et al. [33] .
Why does trimethylamine-N-oxide increase after antiretroviral therapy? It could be argued that the effect might be related to dietary changes and the return of appetite after viral control is established through treatment. However, this argument remains purely hypothetical as we lack data on diet and general well being. Moreover, fatigue and loss of appetite is more pronounced in advanced HIV disease that is not clinically represented in the two study cohorts at baseline.
It could also be argued that ART favours a more TMAprone microbiome. However, we could not find evidence supporting an expansion of TMA-producing bacteria after ART initiation in chronic HIV-1-infected individuals. Notwithstanding, the data concerning TMA production of gut bacteria are not complete and any such analysis should be interpreted cautiously. Notably, phylogeny appears to be a poor predictor of TMA production [29] .
TMAO, inflammation and dysbiosis in HIV-1 Missailidis et al. 1595 Despite the lack of association between TMA-producers and systemic TMAO-levels after ARTwe found a positive correlation between plasma TMAO and Firmicutes at baseline and at follow-up and an inverse correlation with members of Bacteroidetes at baseline with the exception of Prevotella spp. Our observations support published data demonstrating a widespread TMA production propensity among members of Proteobacteria and Firmicutes that appears to be missing in Bacteroidetes [19, 20, 22, 23, 29] . Further, several studies have observed a positive association between Prevotella spp. and TMAO levels [10, 36, 37] , but the underlying mechanisms remain to be elucidated.
Furthermore, although there is no established link between FMO 3 and HIV-1, it could be argued that FMO 3 activity might be affected by ART. Of note, a recent publication presented evidence that FMO 3 was involved in metabolizing F18, a new experimental NNRTI [38] . To our knowledge, no studies have assessed the role of FMO 3 in metabolizing protease inhibitor, or commercially available NNRTI. Whereas Haissman et al. [33] observed that protease inhibitor, but not NNRTI, was associated with increased TMAO levels following ART initiation, we found no significant impact of choice of protease inhibitor or NNRTI on TMAO levels at follow-up (P ¼ 0.17) or changes in TMAO levels (P ¼ 0.21) in the chronic HIV-cohort. Nor did protease inhibitor (P ¼ 0.99) or NNRTI (P ¼ 0.59) predict TMAO levels in the chronic ART cohort. However, although no significant association between protease inhibitor treatment and TMAO levels was established in the chronic HIV-1 cohort, protease inhibitor was the dominating ART in the group with increased TMAO levels at follow-up.
Finally, it is possible that the decreased TMAO levels observed in treatment-naive HIV-1-infected individuals relate to down-regulation of the TMA-converting enzyme FMO 3 by gut-related inflammation, as observed in a model of LPS-induced sepsis in mice [39] . Indirect support of this hypothesis is provided by a recent clinical study, which reported reduced TMAO levels in IBD patients with active disease compared with inactive disease and healthy controls [40] . Moreover, we found a more pronounced loss of Bacteroidetes and higher levels of LPS in chronic HIV-1-infected individuals who did not increase their TMAO levels after ART despite viral control. Loss of Bacteroidetes and increase in Proteobacteria has been linked to increased microbial translocation and systemic inflammation in both HIV and inflammatory bowel disease (IBD) [41, 42] . Finally, chronic HIV-1-infected individuals with no increase in TMAO had lower CD4 þ /CD8 þ ratios at baseline, suggesting that lack of gain in TMAO might serve as a surrogate-marker for a more dysregulated gut immune barrier function that prevails despite effective ART. FMO 3 downregulation may also be attributed to reduction of the bile acid-activated Farnesoid X receptor (FXR). FXR modulates bile acid homeostasis and inflammation in the gut [43] [44] [45] , and is involved in inducing FMO 3 in mice models [16, 36, 46] . Importantly, in HIV patients, downregulation of FXR expression has been observed in monocytes and hepatocytes despite functional ART [47, 48] . However, the link between FXR-expression and TMAO levels is not yet established in clinical cohorts.
The strength of our study is the consistency in trend observed both in longitudinal and cross-sectional study cohorts representing both primary HIV and individuals with chronic HIV infection at different treatment length and matching healthy controls. Moreover, longitudinal data on microbiome composition provided a unique opportunity to assess its relation to TMAO. The limitations of the study include the relatively low number of patients in each cohort, lack of power to study cardiovascular event rate, lack of information regarding MSM status in the control cohorts and lack of dietary data. However, the healthy controls of the chronic HIV-1 cohort consisted of household members and partners of the patients indicating similar sexual orientation and food intake.
In conclusion, although we cannot exclude that elevated TMAO may contribute to cardiovascular risk in general, our data do not support the hypothesis that TMAO is a significant link between gut dysbiosis, inflammation and cardiovascular risk in HIV-1-infected individuals. TMAO levels appear to be disparately regulated by HIV infection, ART and microbiota, thus limiting its role as a cardiovascular risk marker in HIV-infected individuals.
